Bayesian Statistics in Clinical Trials

Bayesian Statistics in Clinical Trials designates a statistical framework incorporating prior knowledge alongside observed trial data to continuously update probability estimates of treatment effects, enabling more flexible trial designs, smaller sample sizes in certain contexts, and formal incorporation of historical data compared to traditional frequentist hypothesis testing approaches.

The biopharmaceutical industry increasingly adopts Bayesian methods in clinical development for adaptive trial designs, dose-finding studies, paediatric extrapolation, and rare disease programmes where limited patient populations preclude large traditional trials. Bayesian adaptive designs modify randomisation ratios, sample sizes, or treatment arms based on accumulating evidence while maintaining prespecified error rate control. Prior distributions encode historical data or biological plausibility, formally borrowing strength from existing evidence. Regulatory agencies including FDA have issued guidance supporting Bayesian approaches. As complex trial designs expand and computational capabilities advance, Bayesian statistics continues transforming clinical development through flexible, efficient evidence generation.